Thibault Bahougne
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Thibault Bahougne has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Eleni Angelopoulou
Institut des Neurosciences Cellulaires et Intégratives, (UPR CNRS 3212) and Université de Strasbourg, Strasbourg, France
2 shared publications L. Kessler
CHU de Strasbourg, service endocrinologie, diabète, et nutrition, médical B, hôpital Civil, Strasbourg, France
2 shared publicationsLaurence Kessler
Service d’Endocrinologie, Diabète et Nutrition, Hôpitaux Universitaires de Strasbourg, 1 Place de L’Hôpital, F-67000, Strasbourg, France
2 shared publications- Valérie Simonneaux
Institut des Neurosciences Cellulaires et Intégratives (CNRS) Strasbourg France
2 shared publications A. Guth
1 shared publicationA. Imperiale
CHU de Strasbourg, service de médecine nucléaire, Strasbourg, France
1 shared publication
Latest Publications
- Open Access
- 19 September 2020
- Published by Springer Nature in BMC Nephrology
- Vol. 21 (1) , 1-6
Atypical hemolytic and uremic syndrome due to C3 mutation in pancreatic islet transplantation: a case report
Background: We here report on the first observation of a C3 mutation that is related to atypical hemolytic and uremic syndrome (aHUS), which occurred in a pancreatic islet transplant patient. Immunosuppressive treatments, such as calcineurin inhibitors, have been linked to undesirable effects like nephrotoxicity. Case presentation: A 40-year-old man with brittle diabetes, who was included in the TRIMECO trial, became insulin-independent 2 months after pancreatic islet transplantation. About 15 months after islet transplantation, the patient exhibited acute kidney injury due to aHUS. Despite plasma exchange and eculizumab treatment, the patient developed end-stage renal disease. A genetic workup identified a missense variant (p.R592Q) in the C3 gene. In vitro, this C3 variant had defective Factor I proteolytic activity with membrane proteins as cofactor proteins, which was thus classified as pathogenic. About 1 year after the aHUS episode, kidney transplantation was carried out under the protection of the specific anti-C5 monoclonal antibody eculizumab. The patient had normal kidney function, with preserved pancreatic islet function 4 years later. Conclusions: Pancreatic islet transplantation could have triggered this aHUS episode, but this link needs to be clarified. Although prophylactic eculizumab maintains kidney allograft function, its efficacy still needs to be studied in larger populations.
- 19 September 2020
- Published by Springer Nature in BMC Nephrology
- Vol. 21 (1) , 1-6
Open AccessAtypical hemolytic and uremic syndrome due to C3 mutation in pancreatic islet transplantation: a case report
Background: We here report on the first observation of a C3 mutation that is related to atypical hemolytic and uremic syndrome (aHUS), which occurred in a pancreatic islet transplant patient. Immunosuppressive treatments, such as calcineurin inhibitors, have been linked to undesirable effects like nephrotoxicity. Case presentation: A 40-year-old man with brittle diabetes, who was included in the TRIMECO trial, became insulin-independent 2 months after pancreatic islet transplantation. About 15 months after islet transplantation, the patient exhibited acute kidney injury due to aHUS. Despite plasma exchange and eculizumab treatment, the patient developed end-stage renal disease. A genetic workup identified a missense variant (p.R592Q) in the C3 gene. In vitro, this C3 variant had defective Factor I proteolytic activity with membrane proteins as cofactor proteins, which was thus classified as pathogenic. About 1 year after the aHUS episode, kidney transplantation was carried out under the protection of the specific anti-C5 monoclonal antibody eculizumab. The patient had normal kidney function, with preserved pancreatic islet function 4 years later. Conclusions: Pancreatic islet transplantation could have triggered this aHUS episode, but this link needs to be clarified. Although prophylactic eculizumab maintains kidney allograft function, its efficacy still needs to be studied in larger populations.
- 26 February 2020
- Published by The Endocrine Society in Endocrinology
- Vol. 161 (4)
Impact of Circadian Disruption on Female Mice Reproductive Function
In female mammals, cycles in reproductive function depend both on the biological clock synchronized to the light/dark cycle and on a balance between the negative and positive feedbacks of estradiol, whose concentration varies during oocyte maturation. In women, studies report that chronodisruptive environments such as shiftwork may impair fertility and gestational success. The objective of this study was to explore the effects of shifted light/dark cycles on both the robustness of the estrous cycles and the timing of the preovulatory luteinizing hormone (LH) surge in female mice. When mice were exposed to a single 10-hour phase advance or 10-hour phase delay, the occurrence and timing of the LH surge and estrous cyclicity were recovered at the third estrous cycle. By contrast, when mice were exposed to chronic shifts (successive rotations of 10-hoursour phase advances for 3 days followed by 10-hour phase delays for 4 days), they exhibited a severely impaired reproductive activity. Most mice had no preovulatory LH surge at the beginning of the chronic shifts. Furthermore, the gestational success of mice exposed to chronic shifts was reduced, because the number of pups was 2 times lower in shifted than in control mice. In conclusion, this study reports that exposure of female mice to a single phase shift has minor reproductive effects, whereas exposure to chronically disrupted light/dark cycles markedly impairs the occurrence of the preovulatory LH surge, leading to reduced fertility.
- 26 February 2020
- Published by The Endocrine Society in Endocrinology
- Vol. 161 (4)
Impact of Circadian Disruption on Female Mice Reproductive Function
In female mammals, cycles in reproductive function depend both on the biological clock synchronized to the light/dark cycle and on a balance between the negative and positive feedbacks of estradiol, whose concentration varies during oocyte maturation. In women, studies report that chronodisruptive environments such as shiftwork may impair fertility and gestational success. The objective of this study was to explore the effects of shifted light/dark cycles on both the robustness of the estrous cycles and the timing of the preovulatory luteinizing hormone (LH) surge in female mice. When mice were exposed to a single 10-hour phase advance or 10-hour phase delay, the occurrence and timing of the LH surge and estrous cyclicity were recovered at the third estrous cycle. By contrast, when mice were exposed to chronic shifts (successive rotations of 10-hoursour phase advances for 3 days followed by 10-hour phase delays for 4 days), they exhibited a severely impaired reproductive activity. Most mice had no preovulatory LH surge at the beginning of the chronic shifts. Furthermore, the gestational success of mice exposed to chronic shifts was reduced, because the number of pups was 2 times lower in shifted than in control mice. In conclusion, this study reports that exposure of female mice to a single phase shift has minor reproductive effects, whereas exposure to chronically disrupted light/dark cycles markedly impairs the occurrence of the preovulatory LH surge, leading to reduced fertility.
- 23 October 2019
- Published by Springer Nature in GeroScience
- Vol. 42 (1) , 323-331
Individual evaluation of luteinizing hormone in aged C57BL/6 J female mice
In female mammals, reproductive senescence is a complex process involving progressive ovarian dysfunction associated with an altered central control of the hypothalamic-pituitary axis. The objective of this study was to compare the longitudinal change in preovulatory luteinizing hormone (LH) secretion as well as estrous cycle in individual C57BL/6 J female mice at 3, 6, 9 and 12 months. Amplitude and timing of LH secretion at the surge were similar from 3 to 9 months but were altered in 12-month old mice with a significant decrease of more than 50% of peak LH value and a 2 h delay in the occurrence of the LH surge as compared to younger mice. The analysis of two to three successive LH surges at 3, 6, 9 and 12 months showed low and similar intra-individual variability at all ages. The estrous cycle length and intra/inter variability were stable over the age. This study shows that female mice in regular environmental conditions display stable LH surge timing and amplitude up to 9 months, but at 12 months, the LH surge is delayed with a reduced amplitude, however without overt modification in the estrous cycles. Analysis of individual preovulatory LH secretion and estrous cycle indicates that mice can be followed up to 9 months to investigate the detrimental effects of various parameters on mouse reproductive activity.
- 23 October 2019
- Published by Springer Nature in GeroScience
- Vol. 42 (1) , 323-331
Individual evaluation of luteinizing hormone in aged C57BL/6 J female mice
In female mammals, reproductive senescence is a complex process involving progressive ovarian dysfunction associated with an altered central control of the hypothalamic-pituitary axis. The objective of this study was to compare the longitudinal change in preovulatory luteinizing hormone (LH) secretion as well as estrous cycle in individual C57BL/6 J female mice at 3, 6, 9 and 12 months. Amplitude and timing of LH secretion at the surge were similar from 3 to 9 months but were altered in 12-month old mice with a significant decrease of more than 50% of peak LH value and a 2 h delay in the occurrence of the LH surge as compared to younger mice. The analysis of two to three successive LH surges at 3, 6, 9 and 12 months showed low and similar intra-individual variability at all ages. The estrous cycle length and intra/inter variability were stable over the age. This study shows that female mice in regular environmental conditions display stable LH surge timing and amplitude up to 9 months, but at 12 months, the LH surge is delayed with a reduced amplitude, however without overt modification in the estrous cycles. Analysis of individual preovulatory LH secretion and estrous cycle indicates that mice can be followed up to 9 months to investigate the detrimental effects of various parameters on mouse reproductive activity.
- Open Access
- 23 May 2018
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 7 (6) , 116
Functioning Mediastinal Paraganglioma Associated with a Germline Mutation of von Hippel-Lindau Gene
We report the case of a 21-year old woman presenting with high blood pressure and raised normetanephrine levels. Indium-111-pentetreotide single photon-emission computed tomography with computed tomography (SPECT/CT) and 2-deoxy-2-[fluorine-18]fluoro-d-glucose (FDG) positron emission tomography/computed tomography (PET/CT) imaging showing isolated tracer-uptake by a 2 cm tumor close to the costovertebral angle of the third thoracic vertebra. Thoracic surgery led to normalization of normetanephrine levels. Histological findings were consistent with the presence of a paraganglioma. Mutations in SDHA, SDHB, SDHC, SDHD, RET, SDHAF2, TMEM127, MAX, NF1, FH, MDH2, and EPAS1 were absent, but a heterozygous missense mutation, c.311G > T, was found in exon 1 of the von Hippel-Lindau gene, VHL, resulting in a glycine to valine substitution in the VHL protein at position 104, p.Gly104Val. This same mutation was found in both the mother and the 17-year old sister in whom a small retinal hemangioblastoma was also found. We diagnose an unusual functional mediastinal paraganglioma in this young patient with a germline VHL gene mutation, a mutation previously described as inducing polycythemia and/or pheochromocytoma but not paraganglioma or retinal hemangioblastoma.
- 23 May 2018
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 7 (6) , 116
Open AccessFunctioning Mediastinal Paraganglioma Associated with a Germline Mutation of von Hippel-Lindau Gene
We report the case of a 21-year old woman presenting with high blood pressure and raised normetanephrine levels. Indium-111-pentetreotide single photon-emission computed tomography with computed tomography (SPECT/CT) and 2-deoxy-2-[fluorine-18]fluoro-d-glucose (FDG) positron emission tomography/computed tomography (PET/CT) imaging showing isolated tracer-uptake by a 2 cm tumor close to the costovertebral angle of the third thoracic vertebra. Thoracic surgery led to normalization of normetanephrine levels. Histological findings were consistent with the presence of a paraganglioma. Mutations in SDHA, SDHB, SDHC, SDHD, RET, SDHAF2, TMEM127, MAX, NF1, FH, MDH2, and EPAS1 were absent, but a heterozygous missense mutation, c.311G > T, was found in exon 1 of the von Hippel-Lindau gene, VHL, resulting in a glycine to valine substitution in the VHL protein at position 104, p.Gly104Val. This same mutation was found in both the mother and the 17-year old sister in whom a small retinal hemangioblastoma was also found. We diagnose an unusual functional mediastinal paraganglioma in this young patient with a germline VHL gene mutation, a mutation previously described as inducing polycythemia and/or pheochromocytoma but not paraganglioma or retinal hemangioblastoma.
- 1 October 2017
- Published by Elsevier in Best Practice & Research Clinical Endocrinology & Metabolism
- Vol. 31 (5) , 505-519
Daily rhythms count for female fertility
- 1 October 2017
- Published by Elsevier in Best Practice & Research Clinical Endocrinology & Metabolism
- Vol. 31 (5) , 505-519
Daily rhythms count for female fertility
- 1 February 2017
- Published by Bioscientifica in Endocrine-Related Cancer
- Vol. 24 (2) , L7-L11
Successful response to pegylated interferon alpha in a patient with recurrent paraganglioma
Introduction: Early and accurate identification of recurrences in patients with aggressive paraganglioma (PGL) poses significant challenges. Moreover, the most appropriate therapeutic strategy for recurrent PGL remains to be established. Results: We report the case of 52-year-old man with a history of recurrent, sporadic, left retroperitoneal PGL that relapsed twice (at eight and nine years after the first surgical intervention). At the time of the second recurrence, 2-deoxy-2-[fluorine-18]fluoro-D-glucose (FDG) positron emission tomography/computed tomography (PET/CT) demonstrated a pathologically increased tracer uptake in multiple nodular lesions (10−15 mm in size) located close to the remnant of the left renal pedicle and in the left lombar paravertebral region. Moreover, PET/CT showed a hypermetabolic left supraclavicular lymph node (suggestive of a metastatic disease). Owing to the high surgical risk inherent in a third surgical intervention, the French network for adrenal cancers (COMETE-Cancer) board proposed medical treatment with pegylated interferon alpha (Pegasys; 180 µg per week). After one year of treatment, a 30% decrease in urinary normetanephrine levels was observed. In addition, a marked morpho-metabolic regression of nearly all of the retroperitoneal lesions as well as of the left supraclavicular lymph node was evident. Unfortunately, the patient developed significant signs of drug intolerance, leading to dose tapering and treatment discontinuation. Conclusion: This is the first case of recurrent PGL that showed significant biological and imaging responses to medical treatment with pegylated interferon alpha. Further research on the potential usefulness of this therapeutic approach in patients with relapsing PGL or pheochromocytoma is warranted.
- 1 February 2017
- Published by Bioscientifica in Endocrine-Related Cancer
- Vol. 24 (2) , L7-L11
Successful response to pegylated interferon alpha in a patient with recurrent paraganglioma
Introduction: Early and accurate identification of recurrences in patients with aggressive paraganglioma (PGL) poses significant challenges. Moreover, the most appropriate therapeutic strategy for recurrent PGL remains to be established. Results: We report the case of 52-year-old man with a history of recurrent, sporadic, left retroperitoneal PGL that relapsed twice (at eight and nine years after the first surgical intervention). At the time of the second recurrence, 2-deoxy-2-[fluorine-18]fluoro-D-glucose (FDG) positron emission tomography/computed tomography (PET/CT) demonstrated a pathologically increased tracer uptake in multiple nodular lesions (10−15 mm in size) located close to the remnant of the left renal pedicle and in the left lombar paravertebral region. Moreover, PET/CT showed a hypermetabolic left supraclavicular lymph node (suggestive of a metastatic disease). Owing to the high surgical risk inherent in a third surgical intervention, the French network for adrenal cancers (COMETE-Cancer) board proposed medical treatment with pegylated interferon alpha (Pegasys; 180 µg per week). After one year of treatment, a 30% decrease in urinary normetanephrine levels was observed. In addition, a marked morpho-metabolic regression of nearly all of the retroperitoneal lesions as well as of the left supraclavicular lymph node was evident. Unfortunately, the patient developed significant signs of drug intolerance, leading to dose tapering and treatment discontinuation. Conclusion: This is the first case of recurrent PGL that showed significant biological and imaging responses to medical treatment with pegylated interferon alpha. Further research on the potential usefulness of this therapeutic approach in patients with relapsing PGL or pheochromocytoma is warranted.
- 9 September 2015
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 76 (4) , 513
Effet inhibiteur de l’iterféron-alpha sur un paragangliome abdominal récidivant
- 9 September 2015
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 76 (4) , 513
Effet inhibiteur de l’iterféron-alpha sur un paragangliome abdominal récidivant
- 1 March 2015
- Published by Elsevier in Diabetes & Metabolism
- Vol. 41, A31
PO33 Greffe combinée de poumon et d’îlots pancréatiques : une nouvelle alternative thérapeutique dans la mucoviscidose
- 1 March 2015
- Published by Elsevier in Diabetes & Metabolism
- Vol. 41, A31
PO33 Greffe combinée de poumon et d’îlots pancréatiques : une nouvelle alternative thérapeutique dans la mucoviscidose
- 1 September 2013
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 74 (4) , 381
Paragangliome médiastinal sécrétant, dans le cadre d’une maladie de Von Hippel Lindau : mise en évidence d’une nouvelle mutation du gène VHL
- 1 September 2013
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 74 (4) , 381
Paragangliome médiastinal sécrétant, dans le cadre d’une maladie de Von Hippel Lindau : mise en évidence d’une nouvelle mutation du gène VHL